Bachem Holding AG - Asset Resilience Ratio
Bachem Holding AG (BANB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bachem Holding AG short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Bachem Holding AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BANB total assets.
Liquid Assets Composition Over Time
This chart breaks down Bachem Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Bachem Holding AG debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bachem Holding AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bachem Holding AG Industry Peers by Asset Resilience Ratio
Compare Bachem Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Bachem Holding AG (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Bachem Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF1.92 Billion ≈ $2.43 Billion |
-- |
| 2023-12-31 | 8.37% | CHF140.80 Million ≈ $178.01 Million |
CHF1.68 Billion ≈ $2.13 Billion |
-8.76pp |
| 2022-12-31 | 17.12% | CHF236.98 Million ≈ $299.60 Million |
CHF1.38 Billion ≈ $1.75 Billion |
-10.07pp |
| 2021-12-31 | 27.20% | CHF353.17 Million ≈ $446.50 Million |
CHF1.30 Billion ≈ $1.64 Billion |
+26.80pp |
| 2013-12-31 | 0.40% | CHF1.73 Million ≈ $2.19 Million |
CHF438.78 Million ≈ $554.73 Million |
-0.26pp |
| 2008-12-31 | 0.66% | CHF3.01 Million ≈ $3.80 Million |
CHF457.32 Million ≈ $578.17 Million |
-2.46pp |
| 2007-12-31 | 3.12% | CHF13.39 Million ≈ $16.93 Million |
CHF429.07 Million ≈ $542.46 Million |
-9.59pp |
| 2006-12-31 | 12.71% | CHF56.20 Million ≈ $71.05 Million |
CHF442.24 Million ≈ $559.10 Million |
+1.03pp |
| 2005-12-31 | 11.68% | CHF47.69 Million ≈ $60.29 Million |
CHF408.21 Million ≈ $516.09 Million |
-- |
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commerci… Read more